Stock Analysis

CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%

BOVESPA:VVEO3
Source: Shutterstock

The CM Hospitalar S/A (BVMF:VVEO3) share price has fared very poorly over the last month, falling by a substantial 49%. For any long-term shareholders, the last month ends a year to forget by locking in a 79% share price decline.

Following the heavy fall in price, CM Hospitalar S/A may be sending very bullish signals at the moment with its price-to-earnings (or "P/E") ratio of 3.5x, since almost half of all companies in Brazil have P/E ratios greater than 11x and even P/E's higher than 18x are not unusual. However, the P/E might be quite low for a reason and it requires further investigation to determine if it's justified.

Recent times have been advantageous for CM Hospitalar S/A as its earnings have been rising faster than most other companies. It might be that many expect the strong earnings performance to degrade substantially, which has repressed the P/E. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

Check out our latest analysis for CM Hospitalar S/A

pe-multiple-vs-industry
BOVESPA:VVEO3 Price to Earnings Ratio vs Industry May 11th 2024
Want the full picture on analyst estimates for the company? Then our free report on CM Hospitalar S/A will help you uncover what's on the horizon.

Is There Any Growth For CM Hospitalar S/A?

In order to justify its P/E ratio, CM Hospitalar S/A would need to produce anemic growth that's substantially trailing the market.

Retrospectively, the last year delivered an exceptional 51% gain to the company's bottom line. The strong recent performance means it was also able to grow EPS by 86% in total over the last three years. So we can start by confirming that the company has done a great job of growing earnings over that time.

Shifting to the future, estimates from the eight analysts covering the company suggest earnings growth is heading into negative territory, declining 7.2% over the next year. That's not great when the rest of the market is expected to grow by 19%.

In light of this, it's understandable that CM Hospitalar S/A's P/E would sit below the majority of other companies. Nonetheless, there's no guarantee the P/E has reached a floor yet with earnings going in reverse. Even just maintaining these prices could be difficult to achieve as the weak outlook is weighing down the shares.

The Final Word

CM Hospitalar S/A's P/E looks about as weak as its stock price lately. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.

As we suspected, our examination of CM Hospitalar S/A's analyst forecasts revealed that its outlook for shrinking earnings is contributing to its low P/E. Right now shareholders are accepting the low P/E as they concede future earnings probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.

We don't want to rain on the parade too much, but we did also find 5 warning signs for CM Hospitalar S/A (2 can't be ignored!) that you need to be mindful of.

Of course, you might also be able to find a better stock than CM Hospitalar S/A. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.